Top 10 Companies in the (S)-N-Benzyl-1-phenyl ethylamine (CAS 17480-69-2) Market (2026): Market Leaders Driving Global Chiral Chemistry

MARKET INSIGHTS

Global (S)-N-Benzyl-1-phenyl ethylamine (CAS 17480-69-2) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.7 million by 2034, exhibiting a CAGR of 7.3% during the forecast period.

(S)-N-Benzyl-1-phenyl ethylamine (CAS 17480-69-2) is a chiral amine widely utilized as a resolving agent and chiral auxiliary in asymmetric synthesis. Its well‑defined stereochemical configuration makes it particularly valuable in pharmaceutical manufacturing, where enantiomeric purity is critical to drug efficacy and safety. The compound serves as a key building block in the synthesis of optically active intermediates across active pharmaceutical ingredient (API) production workflows.

The market is gaining steady traction driven by the expanding global demand for enantiopure compounds in drug development and the growing emphasis on green chemistry practices in fine chemical manufacturing. Increasing investments in chiral chemistry research and the rising prevalence of stereoselective synthesis across pharmaceutical pipelines continue to broaden the compound’s application scope. Companies such as MilliporeSigma (Merck KGaA), Tokyo Chemical Industry (TCI), and Alfa Aesar are among the recognized suppliers active in this space.

(S)-N-Benzyl-1-phenyl ethylamine (CAS 17480-69-2) Market – View in Detailed Research Report

Top 10 Companies in the (S)-N-Benzyl-1-phenyl ethylamine Market

1. MilliporeSigma (Merck KGaA)

Headquarters: Rahway, New Jersey, USA (Global operations in Germany and USA)

Key Offering: High‑purity chiral amines, custom synthesis services, and analytical support for enantiomeric analysis.

MilliporeSigma leverages its extensive research chemistry portfolio to deliver chiral intermediates that meet the stringent quality expectations of pharmaceutical clients. The company’s integrated platform enables rapid scale‑up from laboratory to pilot‑scale, reducing time‑to‑market for new drug candidates.

Sustainability & Growth Initiatives:

• Implementation of green solvent protocols and waste‑reduction programs in synthesis routes.
• Investment in continuous‑flow processing to improve atom economy.
• Collaboration with academic partners to develop next‑generation chiral catalysts.

2. Tokyo Chemical Industry (TCI)

Headquarters: Tokyo, Japan

Key Offering: Comprehensive catalog of chiral building blocks, including (S)-N-Benzyl-1-phenyl ethylamine, with a focus on high optical purity.

TCI’s manufacturing footprint in Japan and overseas facilities ensures reliable supply to the Asia‑Pacific market. The company routinely supports custom synthesis projects for pharmaceutical and fine‑chemical customers, maintaining tight control over batch consistency.

Sustainability & Growth Initiatives:

• Adoption of renewable feedstock sourcing for key starting materials.
• Development of enzymatic resolution processes to lower energy consumption.
• Active participation in industry forums to harmonize chiral purity standards.

3. Alfa Aesar (Thermo Fisher Scientific)

Headquarters: Albany, New York, USA

Key Offering: Broad range of fine chemicals and chiral reagents, with a strong emphasis on research‑grade purity.

Alfa Aesar’s distribution network spans North America, Europe, and Asia, enabling rapid delivery for academic and industrial laboratories. The company’s quality management system supports rigorous analytical validation for each batch.

Sustainability & Growth Initiatives:

• Implementation of a closed‑loop waste treatment system for solvent recycling.
• Investment in high‑throughput screening to identify greener synthetic routes.
• Strategic alliances with contract manufacturers to expand API intermediates portfolio.

4. Fluorochem Ltd.

Headquarters: Cambridge, United Kingdom

Key Offering: Specialty chiral reagents and custom synthesis services for the European market.

Fluorochem’s expertise in stereoselective chemistry is complemented by its robust quality assurance program, ensuring that each batch meets pharmacopeial standards.

Sustainability & Growth Initiatives:

• Use of biodegradable solvents in laboratory‑scale reactions.
• Collaboration with EU research consortia to develop catalytic enantioselective processes.
• Commitment to ISO 14001 environmental management certification.

5. Jinan Aoks Chemical Co., Ltd.

Headquarters: Jinan, China

Key Offering: Commercial production of (S)-N-Benzyl-1-phenyl ethylamine for API intermediates and research markets.

Jinan Aoks has scaled up its production capacity to meet the growing demand from Asia‑Pacific pharmaceutical manufacturers, while maintaining high optical purity through in‑house resolution processes.

Sustainability & Growth Initiatives:

• Adoption of renewable energy sources in manufacturing facilities.
• Implementation of a zero‑waste policy for by‑products.
• Participation in China’s Green Chemistry Initiative to reduce hazardous waste.

6. Shaanxi Dideu Medichem Co., Ltd.

Headquarters: Xi’an, China

Key Offering: Production of high‑purity chiral amines and support for contract development and manufacturing organizations (CDMOs).

The company’s strategic location in the western Chinese chemical cluster enables efficient logistics to domestic and export markets.

Sustainability & Growth Initiatives:

• Investments in energy‑efficient reactors to lower carbon footprint.
• Development of scalable biocatalytic resolution platforms.
• Alignment with REACH‑compliant processes for global distribution.

7. Nanjing Chemlin Chemical Industry Co., Ltd.

Headquarters: Nanjing, China

Key Offering: Specialty fine chemicals, including (S)-N-Benzyl-1-phenyl ethylamine, with a focus on high optical purity for API manufacturing.

Chemlin’s integration of quality control laboratories ensures consistent batch performance across large‑scale production runs.

Sustainability & Growth Initiatives:

• Implementation of water‑recycling systems to reduce consumption.
• Exploration of bio‑based feedstocks for starting materials.
• Collaboration with regional universities for process optimization research.

8. Aceto Corporation

Headquarters: San Diego, California, USA

Key Offering: Custom synthesis of chiral amines and intermediates for pharmaceutical and specialty chemical markets.

Aceto’s expertise in stereoselective synthesis supports clients seeking tailored solutions for complex drug candidates.

Sustainability & Growth Initiatives:

• Adoption of solvent‑free synthesis protocols where feasible.
• Investment in high‑throughput screening for catalyst discovery.
• Commitment to carbon‑neutral operations by 2035.

9. Atul Ltd. – Fine Chemicals Division

Headquarters: Pune, India

Key Offering: Production of high‑purity chiral intermediates for the Indian pharmaceutical sector and export markets.

Atul’s focus on quality and regulatory compliance positions it as a trusted partner for contract manufacturers in the region.

Sustainability & Growth Initiatives:

• Implementation of green chemistry training programs for staff.
• Use of renewable energy in manufacturing facilities.
• Partnerships with Indian research institutes for process development.

10. ABCR GmbH

Headquarters: Bielefeld, Germany

Key Offering: Specialty fine chemicals and chiral building blocks for pharmaceutical and academic customers.

ABCR’s robust analytical capabilities ensure that each batch meets the highest standards of optical purity and chemical integrity.

Sustainability & Growth Initiatives:

• Adoption of low‑toxicity solvents in synthesis processes.
• Continuous improvement of energy efficiency across production lines.
• Engagement in EU green chemistry networks to drive industry standards.

Download FREE Sample Report: (S)-N-Benzyl-1-phenyl ethylamine (CAS 17480-69-2) Market – View in Detailed Research Report

Get Full Report: (S)-N-Benzyl-1-phenyl ethylamine (CAS 17480-69-2) Market – View in Detailed Research Report

Outlook

The trajectory of the (S)-N-Benzyl-1-phenyl ethylamine market is underpinned by a steady rise in the number of single‑enantiomer drug candidates. As regulatory agencies worldwide continue to enforce stringent stereochemical characterization, the demand for reliable, high‑purity chiral intermediates will remain robust. The expanding footprint of contract development and manufacturing organizations (CDMOs) in the Asia‑Pacific region further supports a stable supply chain, positioning the market for consistent growth through 2034.

Future Trends

Emerging developments in biocatalytic resolution and asymmetric catalysis are poised to reshape the competitive landscape. Companies that invest in enzymatic platforms and continuous‑flow synthesis will likely capture a larger share of the market, as these technologies offer superior atom economy and lower environmental impact. Parallel to this, the rise of digital procurement platforms is expected to democratise access to niche chiral reagents, expanding the customer base beyond traditional pharmaceutical manufacturers to include a broader spectrum of academic and industrial research labs.